Target intelligence / Profile preview

Desmoglein 3 (DSG3) mRNA (DSG3 mRNA)

Target
DSG3 mRNA
Molecular classification
Messenger RNA, Cadherin family, Cell adhesion molecule
01

Overview

Desmoglein 3 (DSG3) mRNA encodes a calcium-dependent transmembrane glycoprotein that is a critical component of desmosomes, the intercellular junctions responsible for maintaining the structural integrity of stratified squamous epithelia (UniProt: P32926). The protein product of this mRNA facilitates cell-cell adhesion by interacting with other desmogleins and desmocollins, effectively anchoring the intermediate filament network to the plasma membrane (NCBI Gene: 1830). DSG3 is clinically significant as the primary autoantigen in Pemphigus Vulgaris, where autoantibodies against the protein lead to the loss of cell adhesion and severe mucosal blistering (PubMed: 15542702). In oncology, DSG3 mRNA is frequently overexpressed in squamous cell carcinomas, particularly in the lung and head and neck, where it promotes tumor cell proliferation and migration (PubMed: 21602877). Furthermore, its high specificity for squamous cell lineages makes it a robust biomarker for differential diagnosis in pulmonary pathology (PubMed: 21602877). Consequently, DSG3 mRNA has emerged as a potential therapeutic target for RNA-based interventions, such as small interfering RNAs (siRNAs), which aim to downregulate its expression to inhibit tumor progression (PubMed: 25670454). Therapeutic development focusing on this mRNA must carefully balance efficacy against the risk of disrupting normal epithelial adhesion in healthy tissues.

Other names
Pemphigus vulgaris antigen mRNAPVA mRNACDHF6 mRNACadherin family member 6 mRNADSG3 transcript
02

Mechanism of action

RNA interference-mediated degradation of DSG3 transcripts and inhibition of protein translation

03

Biological functions

Cell-cell adhesionDesmosome assemblyEpithelial structural integritySignal transduction
04

Disease associations

Pemphigus vulgarisSquamous cell carcinomaHead and neck cancerLung cancer
05

Safety considerations

Epithelial blisteringMucosal toxicityImpaired skin barrier functionOff-target RNA interference
06

Interacting drugs

siRNA-DSG3 (Experimental)

1 more in the full profile.

07

Biomarkers

DSG3 mRNA expression levelsAnti-DSG3 autoantibodiesDSG3 protein immunohistochemistry

Beyond the preview

Go deeper on Desmoglein 3 (DSG3) mRNA (DSG3 mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Desmoglein 3 (DSG3) mRNA (DSG3 mRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call